Companies - March 6, 2015
Novo Nordisk on ‘100 Best Companies’ List
For the seventh consecutive year, Novo Nordisk has made the FORTUNE magazine “100 Best Companies to Work For” list, this year ranking 66th. The hundreds of companies that apply each year are evaluated on five criteria: credibility, respect, fairness, pride and camaraderie by the creator of the list, Great Place to Work®. “We strive to […]
Pharma Business - March 5, 2015
AstraZeneca to Open R&D Site
AstraZeneca is planning to move its antibiotic research and development business into a standalone company at a cost of about $40 million. The plan will affect about 95 people at its facility in Waltham, MA. The focus of the new company will be research and development of AstraZeneca’s early-stage antibiotic pipeline. This will include AZD0914, […]
Acquisition - March 5, 2015
Innokas Signs Two R&D Pacts
Innokas Medical has entered into R&D agreements with two healthcare technology companies operating in central Europe. Both agreements involve new customers for Innokas, and represent an important step in the company’s growth and internationalization. Under the first agreement, which was signed with a company headquartered in France, Innokas will develop a a patient monitoring device. […]
Uncategorized - March 4, 2015
Method Sets Fluid Level for Sepsis Patients
A new procedure under development by Simon Tilma Vistisen, assistant professor at the Research Centre for Emergency Medicine at Finland’s Aarhus University, could help doctors more accurately monitor the amount of fluid a sepsis patient receives. “If this new monitoring method comes into use as early as in the emergency units, the doctors will be […]
Uncategorized - March 4, 2015
Telemedicine Event in April
The 20th Finnish National Conference on Telemedicine and eHealth is scheduled for April 9-10 in Espoo. Among this year’s themes are Nordic collaboration in eHealth innovations, ICT and health, health cybersecurity, prevention and self-management and the health apps revolution. The program is aimed at health care professionals and service providers and will include site visits […]
Drug Development Pharma - March 4, 2015
Progress on Drug for Orphan Disease
Orphazyme, a Danish biotech company working on the development of orphan drugs, recently completed a new series B capital round of 20 million Euro. Kurma Partners and Idinvest Partners joined the existing investor syndicate of Novo A/S, Sunstone Capital and Aescap Venture. The company is working on Arimoclomol, the leading drug candidate for the treatment […]
